Evidence map›Paper›PMID 31673952›Full record

ArticleInternational journal of hematology2020

Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis.

Kazuhito Suzuki, Nobuhiro Tsukada, Noriko Nishimura, Yasuyuki Nagata, Kiyoshi Okazuka, Yuko Mishima, Masahiro Yokoyama, Kaichi Nishiwaki, Tadao Ishida, Shingo Yano and 2 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kazuhito SuzukiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, Kashiwa-shi, Chiba, 277-8567, Japan. kaz-suzuki@jikei.ac.jp.
Nobuhiro TsukadaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Noriko NishimuraDepartment of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yasuyuki NagataDivision of Hematology, Internal Medicine 3, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kiyoshi OkazukaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Yuko MishimaDepartment of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Masahiro YokoyamaDepartment of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kaichi NishiwakiDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, 163-1 Kashiwa-shita, Kashiwa-shi, Chiba, 277-8567, Japan.
Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Shingo YanoDivision of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Yasuhito TeruiDepartment of Hematology Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The combination of bortezomib, lenalidomide, and dexamethasone (VRD) is used as induction treatment in multiple myeloma; however, the optimum schedule for this regimen remains controversial. In this retrospective study, we compared the efficacy and tolerability of twice-weekly VRD (twVRD) and modified VRD-lite in transplant-eligible myeloma patients. Fifty-five patients (median age 61 years) were included; 22 received twVRD (bortezomib [1.3 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneDisease ProgressionFemaleHematopoietic Stem Cell TransplantationHumansKaplan-Meier EstimateLenalidomideMaleMiddle AgedMultiple MyelomaRetrospective StudiesSurvival RateBortezomibDexamethasoneLenalidomideBortezomibInduction treatmentLenalidomideMultiple myelomaPeripheral neuropathy

Identifiers

PMID31673952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.